Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

Chest

Volumn 115, Issue 1, 1999, Pages 12-18

  Pcloquin, Charles A ^a   Namdar, Rocsanna ^b   Singleton, Michael D ^c   Nix, David E ^d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antacids; Bioavailability; Food; Mycobacterium avtum complex; Mycobacterium tuberculosis; Pharmacokinetics; Rifampin

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ETHAMBUTOL; ISONIAZID; MYLANTA; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032929038     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.1.12     Document Type: Article

References (22)

1. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Grit Care Med 1994; 149:13591374
2. Acocella G, Conti R, Luisetti M, et al. Pharmacokinetic studies on antituberculosis regimens in humans. Am Rev Respir Dis 1985; 132:510-515
3. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991; 59-88
4. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial dnigs. Clin Chest Med 1997; 18:79-87
5. Peloquin CA, Jaresko GS, Yong CL, et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agent Chemother 1997; 41:2670-2679
6. Peloquin CA, Namdar R, Nix DE. Effect of foo'd and antacids on the pharmacokinetics (PK) of isoniazid (INII) and (RIF) [abstract]. Am J Hespir Grit Care Med 199S; 157.-A493
7. Anonymous. 1983 Metropolitan height and weight tables. Statistical Bulletin-Metropolitan Life Foundation. 1983; 64:3-9
8. Peloquin ÇA. Rifampin stability [letter]. Ther Drug Monit 1998; 20:450-451
9. Jelliffe RV. Explicit determination of laboratory assay error patterns: a useful aid in therapeutic drug monitoring. ASCP clinical pharmacology check sample 10: No. DM 89-4 (DM 56). Chicago, IL: American Society of Clinical Pathologists, 1989; 1-6
10. Gibakli M, Perrier D. Pliarmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982
11. Jelliffe RW, Schumitzky A, Van Guilder M. User manual for version 10.6 USCPACK collection of PC programs. Los Angeles, CA: Laboratory of Applied Pliarmacokinetics, USC, 1996
12. D'Argenio D, Schumitzky A. ADAPT II user's guide, biomédical simulations resource. Los .Angeles, CA: University of Southern California, 1992
13. Cockroft DV, Gault MIL Prediction of creatinine clearance from serum creatinine. Nephron 1976; 10:31-41
14. Food and Drug Administration. Bioavailability and biocquivalence requirements. Fed Register 1992; 57:17997-18001
15. Purohit SD, Johri SC, Gupta PR, et al. Raiiitidiiie-rifampin interaction. J Assoc Physicians India 1992; 40:308-310
16. Siegler DI, Bryant M, Burley DM, et al. Effect of meals on rifampicin absorption. Lancet 1974; 2:197-198
17. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid, and pyrazinamide. Tnbercle Lung Dis 1995; 76:109-113
18. Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampin. J Clin Phannacol 1983; 23:433-437
19. Hagelund CHU, Wâalilén P, Eiclsaunet W. Absorption of rifampin in gastrectomized patients: effect of meals. Scand J Respir Dis 1977; 58:241-246
20. Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability of food effect. Clin Phannacol Ther 1992; 52:335-341
21. Owens RC, Keung CF, Gardner S, et al. Pharmacokinetic and food effect evaluation of rifapentine in subjects seropositive for the human immunodeficiency virus [abstract A2]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1997; 1
22. Heifets LB. Antituberculosis drugs: anti-microbial activity in fitro. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991; 13-58